A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study (Q35050731)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

zoledronic acid

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Heike E Daldrup-Link

object named as

Heike E Daldrup-Link

7

0 references

13

object named as

Susan M Blaney

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Katherine K Matthay

12

object named as

Katherine K Matthay

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

author name string

Heidi V Russell

1

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Susan G Groshen

2

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Tasnim Ara

3

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Yves A DeClerck

4

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Randy Hawkins

5

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Hollie A Jackson

6

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Araz Marachelian

8

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Andrej Skerjanec

9

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Julie R Park

10

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Howard Katzenstein

11

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Judith G Villablanca

14

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

publication date

12 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Pediatric Blood & Cancer

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

57

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

275-282

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Dose escalation methods in phase I cancer clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117015

8 July 2018

Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117015

8 July 2018

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117015

8 July 2018

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117015

8 July 2018

Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117015

8 July 2018

Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117015

8 July 2018

Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117015

8 July 2018

Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117015

8 July 2018

Bisphosphonate nephrotoxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117015

8 July 2018

Interpretation of biomarkers of bone metabolism in children: impact of growth velocity and body size in healthy children and chronic disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117015

8 July 2018

Low-energy femoral shaft fractures associated with alendronate use.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117015

8 July 2018

Vitamin D status and bone biomarkers in childhood cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117015

8 July 2018

sIL-6R: more than an agonist?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117015

8 July 2018

Short-term safety assessment in the use of intravenous zoledronic acid in children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117015

8 July 2018

A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117015

8 July 2018

Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117015

8 July 2018

Soluble interleukin 6 receptor (sIL-6R) mediates colonic tumor cell adherence to the vascular endothelium: a mechanism for metastatic initiation?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117015

8 July 2018

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117015

8 July 2018

Use of markers of bone turnover for monitoring bone metastases and the response to therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117015

8 July 2018

'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117015

8 July 2018

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117015

8 July 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117015

8 July 2018

The soluble form of interleukin-6 receptor modulates cell proliferation by acute myeloblastic leukemia blast cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117015

8 July 2018

Long-Term Effects of Bisphosphonates on the Growing Skeleton: Studies of Young Patients with Severe Osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117015

8 July 2018

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117015

8 July 2018

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases

1 reference

https://api.crossref.org/works/10.1002/PBC.22821

21 January 2018

Cyclophosphamide/doxorubicin vs. cisplatin/teniposide in the treatment of children older than 12 months of age with disseminated neuroblastoma: a Pediatric Oncology Group Randomized Phase II study

1 reference

https://api.crossref.org/works/10.1002/PBC.22821

21 January 2018

The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.

1 reference

https://api.crossref.org/works/10.1002/PBC.22821

21 January 2018

Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion

1 reference

https://api.crossref.org/works/10.1002/PBC.22821

21 January 2018

Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma.

1 reference

https://api.crossref.org/works/10.1002/PBC.22821

21 January 2018

The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function

1 reference

https://api.crossref.org/works/10.1002/PBC.22821

21 January 2018

Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV.

1 reference

https://api.crossref.org/works/10.1002/PBC.22821

21 January 2018

Intravenous bisphosphonate therapy in children with osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1002/PBC.22821

21 January 2018

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002/PBC.22821

21 January 2018

Bisphosphonate-induced osteopetrosis: novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases

1 reference

https://api.crossref.org/works/10.1002/PBC.22821

21 January 2018

Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status

1 reference

https://api.crossref.org/works/10.1002/PBC.22821

21 January 2018

Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study

1 reference

https://api.crossref.org/works/10.1002/PBC.22821

21 January 2018

The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.

1 reference

https://api.crossref.org/works/10.1002/PBC.22821

21 January 2018

Investigation of interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R) and soluble gp130 (sgp130) in sera of cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/21671363

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels

1 reference

https://pubmed.ncbi.nlm.nih.gov/21671363

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating IL-6 and sIL-6R in patients with hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21671363

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21671363

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequential cyclophosphamide and doxorubicin for induction of complete remission in children with disseminated neuroblastoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21671363

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Release of soluble IL-6 receptor (IL-6sR) in comparison with release of soluble TNF receptors (sTNF-Rs) by PMNs and WBC derived from breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/21671363

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/PBC.22821

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35050731&oldid=1990379486"